MELBOURNE, Australia, March 6 /PRNewswire-FirstCall/ -- Starpharma Holdings Limited announced today that its company information has been made available in Standard & Poor’s Corporation Records Listing Program.
As part of the Program, a full description of Starpharma Holdings has been published in the Daily News Section of Standard Corporation Records, a recognized securities manual for secondary trading in approximately 38 US states under their Blue Sky Laws. Standard Corporation Records is available in print, CD-ROM, and via the Web at www.netadvantage.com, as well as through numerous electronic vendors.
The company information about Starpharma Holdings to be made available includes an in-depth description of Starpharma’s business operations, share price, dividend history, shares outstanding, company financial position, earnings, and a full income statement and balance sheet.
SPHRY: Starpharma’s American Depositary Receipts (ADRs) trade under the code SPHRY (CUSIP number 855563102). Each Starpharma ADR is equivalent to 10 ordinary shares of Starpharma as traded on the Australian Stock Exchange. The ADR program was launched in January 2005 and ADRs now represent 10.2% of issued capital. Participation in S&P’s Records Listing Program will allow brokerage and investment firms to actively promote SPHRY in as many as 38 US states, further increasing liquidity.
The listing is also part of the process that will qualify SPHRY for participation in the new OTCQX International Prime program, which is due to commence shortly. OTCQX aims to enhance the trading range of qualified international issuers from among the thousands of securities electronically traded on the OTC markets.
Starpharma’s ADR program is managed by The Bank of New York and traded by major brokers including Merrill Lynch, Credit Lyonnais, Natexis Bleichroeder, and Pershing LLC. Three further broking firms are expected to be added as Market Makers in SPHRY over the coming weeks.
Company information distributed through the Corporation Records Program is based upon information that Standard & Poor’s considers to be reliable, but neither Standard & Poor’s nor its affiliates warrant its completeness or accuracy, and it should not be relied upon as such. This material is not intended as an offer or solicitation for the purchase or sale of any security or other financial instrument.
Contacts: Starpharma (www.starpharma.com) Ben Rogers Company Secretary +61-3-8532-2702 ben.rogers@starpharma.com S&P Customer contact: Maria Cruz +1-212-438-3671 maria_cruz@standardandpoors.com Media relations contact: Michael Privitera +1-212-438-6679 michael_privitera@standardandpoors.com
Starpharma
CONTACT: Ben Rogers, Company Secretary of Starpharma, +61-3-8532-2702,ben.rogers@starpharma.com; Customers, Maria Cruz of S&P, +1-212-438-3671,maria_cruz@standardandpoors.com; Media, Michael Privitera of S&P,+1-212-438-6679, michael_privitera@standardandpoors.com